MX2021012050A - Formulaciones de proteinas liquidas que contienen agentes reductores de viscosidad. - Google Patents

Formulaciones de proteinas liquidas que contienen agentes reductores de viscosidad.

Info

Publication number
MX2021012050A
MX2021012050A MX2021012050A MX2021012050A MX2021012050A MX 2021012050 A MX2021012050 A MX 2021012050A MX 2021012050 A MX2021012050 A MX 2021012050A MX 2021012050 A MX2021012050 A MX 2021012050A MX 2021012050 A MX2021012050 A MX 2021012050A
Authority
MX
Mexico
Prior art keywords
lowering agents
viscosity
low
formulations containing
formulations
Prior art date
Application number
MX2021012050A
Other languages
English (en)
Inventor
Alisha K Weight
Alyssa M Larson
Alexander M Klibanov
Kevin Love
Alan Crane
Robert S Langer
Original Assignee
Eagle Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Biologics Inc filed Critical Eagle Biologics Inc
Publication of MX2021012050A publication Critical patent/MX2021012050A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61G—TRANSPORT, PERSONAL CONVEYANCES, OR ACCOMMODATION SPECIALLY ADAPTED FOR PATIENTS OR DISABLED PERSONS; OPERATING TABLES OR CHAIRS; CHAIRS FOR DENTISTRY; FUNERAL DEVICES
    • A61G3/00—Ambulance aspects of vehicles; Vehicles with special provisions for transporting patients or disabled persons, or their personal conveyances, e.g. for facilitating access of, or for loading, wheelchairs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se han desarrollado formulaciones farmacéuticas líquidas de bajo volumen, de baja viscosidad, de proteínas; tales formulaciones pueden administrarse rápida y convenientemente por inyección subcutánea o intramuscular, más que por infusión prolongada intravenosa; estas formulaciones incluyen proteínas de bajo peso molecular y/o alto peso molecular, tales como mAbs, y agentes reductores de viscosidad que normalmente son compuestos orgánicos polares espesos, tales como muchos de los GRAS (Lista de compuestos que en general se consideran seguros por la Administración de Alimentos y Fármacos de los Estados Unidos) e ingredientes inactivos inyectables y agentes terapéuticos aprobados por la FDA.
MX2021012050A 2013-09-11 2016-03-10 Formulaciones de proteinas liquidas que contienen agentes reductores de viscosidad. MX2021012050A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361876621P 2013-09-11 2013-09-11
US201461940227P 2014-02-14 2014-02-14
US201461943197P 2014-02-21 2014-02-21
US201461946436P 2014-02-28 2014-02-28
US201461988005P 2014-05-02 2014-05-02
US201462008050P 2014-06-05 2014-06-05
US201462026497P 2014-07-18 2014-07-18
US201462030521P 2014-07-29 2014-07-29

Publications (1)

Publication Number Publication Date
MX2021012050A true MX2021012050A (es) 2021-11-03

Family

ID=51626611

Family Applications (6)

Application Number Title Priority Date Filing Date
MX2016003183A MX2016003183A (es) 2013-09-11 2014-09-11 Formulaciones de proteínas líquidas que contienen agentes reductores de viscosidad.
MX2016003182A MX2016003182A (es) 2013-09-11 2014-09-11 Formulaciones de proteínas líquidas que contienen líquidos iónicos.
MX2021012049A MX2021012049A (es) 2013-09-11 2016-03-10 Formulaciones de proteinas liquidas que contienen agentes reductores de viscosidad.
MX2021012050A MX2021012050A (es) 2013-09-11 2016-03-10 Formulaciones de proteinas liquidas que contienen agentes reductores de viscosidad.
MX2021012048A MX2021012048A (es) 2013-09-11 2016-03-10 Formulaciones de proteinas liquidas que contienen agentes reductores de viscosidad.
MX2021005907A MX2021005907A (es) 2013-09-11 2016-03-10 Formulaciones de proteinas liquidas que contienen liquidos ionicos.

Family Applications Before (3)

Application Number Title Priority Date Filing Date
MX2016003183A MX2016003183A (es) 2013-09-11 2014-09-11 Formulaciones de proteínas líquidas que contienen agentes reductores de viscosidad.
MX2016003182A MX2016003182A (es) 2013-09-11 2014-09-11 Formulaciones de proteínas líquidas que contienen líquidos iónicos.
MX2021012049A MX2021012049A (es) 2013-09-11 2016-03-10 Formulaciones de proteinas liquidas que contienen agentes reductores de viscosidad.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2021012048A MX2021012048A (es) 2013-09-11 2016-03-10 Formulaciones de proteinas liquidas que contienen agentes reductores de viscosidad.
MX2021005907A MX2021005907A (es) 2013-09-11 2016-03-10 Formulaciones de proteinas liquidas que contienen liquidos ionicos.

Country Status (16)

Country Link
US (12) US10179172B2 (es)
EP (7) EP3043775B1 (es)
JP (11) JP6412575B2 (es)
KR (5) KR102295633B1 (es)
CN (7) CN105848636B (es)
AU (10) AU2014318637B2 (es)
CA (4) CA2924069C (es)
ES (4) ES2837629T3 (es)
HK (5) HK1225982A1 (es)
IL (3) IL275388B1 (es)
MX (6) MX2016003183A (es)
RU (2) RU2710542C2 (es)
SG (6) SG10201809401XA (es)
SI (4) SI3043776T1 (es)
WO (4) WO2015038782A1 (es)
ZA (4) ZA201601968B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2544719T (lt) 2010-03-12 2019-10-25 Debiopharm Int Sa Cd37 surišančios molekulės, ir jų imunokonjugatai
JP6018622B2 (ja) 2011-04-01 2016-11-02 イミュノジェン， インコーポレイテッド Ｃｄ３７結合性分子及びその免疫複合体
US20140348719A1 (en) * 2013-03-14 2014-11-27 Bureau Veritas Pharmaceutical compound stabilizing filter compositions and methods of making and using same
EP3043775B1 (en) 2013-09-11 2020-11-04 Eagle Biologics, Inc. Liquid protein formulations containing viscosity-lowering agents
HUE047699T2 (hu) * 2013-12-17 2020-05-28 Hoffmann La Roche Eljárások rákbetegségek kezelésére PD-1-tengelyhez kötõdõ antagonisták és taxánok alkalmazásával
US20160074515A1 (en) * 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
KR102497368B1 (ko) 2014-10-01 2023-02-10 이글 바이올로직스 인코포레이티드 점도-저하제를 함유하는 폴리삭카라이드 및 핵산 제형
MX2017015039A (es) 2015-06-08 2018-08-09 Debiopharm Int Sa Combinaciones de inmunoconjugado anti-cd37 y anticuerpo anti-cd20.
KR20180018538A (ko) 2015-06-17 2018-02-21 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
TWI797060B (zh) * 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
JP6720293B2 (ja) * 2015-08-19 2020-07-08 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 安定な抗ｉｆｎａｒ１製剤
CA2995243A1 (en) 2015-08-28 2017-03-09 Debiopharm International, S.A. Antibodies and assays for detection of cd37
WO2017049205A2 (en) * 2015-09-18 2017-03-23 Amunix Operating Inc. Growth hormone formulation
WO2017055966A1 (en) * 2015-10-01 2017-04-06 Pfizer Inc. Low viscosity antibody compositions
CA3129181C (en) 2015-10-23 2023-10-31 Reform Biologics, Llc Excipient compounds for biopolymer formulations
CN108289951A (zh) * 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 抗-因子d抗体和缀合物
CN109152831A (zh) * 2015-12-29 2019-01-04 安口生物公司 贝伐珠单抗的缓冲制剂
CN105699555B (zh) * 2016-03-24 2018-09-11 中国标准化研究院 一种丙烯基乙基愈创木酚的液相色谱制备方法
EP3448428A4 (en) * 2016-04-25 2019-11-27 Medimmune, LLC COMPOSITIONS COMPRISING ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODY CO-FORMULATION
KR20230058733A (ko) * 2016-05-05 2023-05-03 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Il-6 및 cd126을 표적으로하는 dna 단일 클론 항체
PL3500856T3 (pl) * 2016-08-18 2021-04-19 Regeneron Pharmaceuticals, Inc. Oznaczenie umożliwiające określenie potencjału białka do samoasocjacji za pomocą spektroskopii zależnych od stężenia samoodziaływań nanocząstek (CD-SINS)
US10463733B1 (en) 2016-10-04 2019-11-05 United States of America as represented by the Secetary of the Air Force Ultra-stable protein ionic liquids
US11274137B1 (en) 2016-10-04 2022-03-15 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
US11274163B1 (en) 2016-10-04 2022-03-15 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
US11385201B1 (en) 2019-09-30 2022-07-12 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
US11382976B1 (en) 2016-10-04 2022-07-12 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
US11274289B1 (en) 2016-10-04 2022-03-15 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
SG10201913049QA (en) * 2016-10-27 2020-02-27 Eisai R&D Man Co Ltd Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease
CN110121340B (zh) * 2016-11-02 2023-03-31 波拉里集团 聚乙二醇化精氨酸脱亚氨酶的调配物
EP3535297B1 (en) 2016-11-02 2022-08-10 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
CA3053909A1 (en) * 2017-02-16 2018-08-23 Reform Biologics, Llc Excipient compounds for protein processing
JOP20190204A1 (ar) * 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
US10238600B2 (en) 2017-04-13 2019-03-26 Richard C. Fuisz Package, system and methods for custody and control of drugs, and method and composition for making an oral soluble film, containing at least one active agent
US9901545B1 (en) 2017-04-13 2018-02-27 Richard C. Fuisz Method and composition for making an oral soluble film, containing at least one active agent
US11639391B2 (en) 2017-04-18 2023-05-02 Dr. Reddy's Laboratories Limited Stable liquid pharmaceutical composition
MA48461A (fr) * 2017-04-28 2020-03-04 Amgen Inc Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
CA3063324A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
CN111032092A (zh) * 2017-06-30 2020-04-17 韩国科学技术院 Vegf-grab蛋白与药物的缀合物及其用途
BR112020003498A2 (pt) * 2017-08-22 2020-08-25 Biogen Ma, Inc. composições farmacêuticas e regimes de dosagem que contêm anticorpos anti-alfa(v)beta(6)
CN111107873A (zh) * 2017-09-05 2020-05-05 默沙东公司 用于降低生物制剂粘度的化合物
CA3082070A1 (en) * 2017-11-07 2019-05-16 Alphacore Pharma Llc Methods of treating and protecting against cardiac disease, cardiovascular disease and related conditions and symptoms
CN111918644A (zh) * 2017-11-17 2020-11-10 哈佛大学校长及研究员协会 用于内部递送的离子液体
CN108096185A (zh) * 2017-12-20 2018-06-01 珠海冀百康生物科技有限公司 一种速效胰岛素制剂及其制备方法
CN112040931A (zh) * 2018-03-07 2020-12-04 改进生物制品有限责任公司 用于蛋白质制剂的赋形剂化合物
JP7465814B2 (ja) * 2018-04-16 2024-04-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 高濃度タンパク質製剤の粘度低下
CN108671229B (zh) * 2018-05-08 2022-03-25 华博生物医药技术（上海）有限公司 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂
KR20200010103A (ko) * 2018-07-19 2020-01-30 (주)셀트리온 안정한 액체 약제학적 제제
WO2020106948A1 (en) * 2018-11-21 2020-05-28 Regeneron Pharmaceuticals, Inc. High concentration protein formulation
US11058770B1 (en) * 2019-01-24 2021-07-13 United States Of America As Represented By The Secretary Of The Air Force Ultrastable antibody ionic liquids
CR20210435A (es) 2019-02-18 2021-09-20 Lilly Co Eli Formulación de anticuerpos terapéuticos
EP3771463A1 (en) 2019-07-29 2021-02-03 Ludwig-Maximilians-Universität München Stabilizing therapeutic proteins with piperazin- or morpholine-containing zwitterionic buffering substances
BR112022004674A2 (pt) * 2019-09-17 2022-06-07 Merck Patent Gmbh Ácido canforsulfônico e combinações do mesmo com excipientes catiônicos como agentes de redução de viscosidade em formulações de proteína altamente concentradas
US11684594B2 (en) 2020-05-12 2023-06-27 President And Fellows Of Harvard College Antifungal prophylaxis for cornea
IL301024A (en) * 2020-09-01 2023-05-01 I2O Therapeutics Inc Ionic liquid formulations for the treatment of diabetes
CN113249358B (zh) * 2021-05-14 2022-10-14 天津大学 一种利用离子液体调控溶菌酶晶型的方法
WO2023278821A2 (en) * 2021-07-01 2023-01-05 Upkara, Inc. Superconcentrated formulations of bioactive agents
CN115350330B (zh) * 2022-09-01 2023-10-20 北京化工大学 一种负电性小分子调控的表面在蛋白差异性黏附上的应用

Family Cites Families (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US190082A (en) 1877-04-24 Improvement in apparatus for cooling liquids
GB750373A (en) 1953-01-15 1956-06-13 Pfizer & Co C Improvements in or relating to injectable suspension of penicillin salts
DK128416B (da) 1964-08-13 1974-04-29 Ciba Geigy Ag Analogifremgangsmåde til fremstilling af adrenocorticotropt aktive nonadecapeptidamider eller syreadditionssalte eller kompleksforbindelser deraf.
BE757195A (fr) 1969-10-07 1971-03-16 Century Disposable Devices Seringue servant a injecter un melange fraichement prepare de poudre etde liquide
JPS5270014A (en) 1975-12-05 1977-06-10 Senju Pharma Co Stabilization of pyrido*3*22a*phenoxadine compounds
US4171698A (en) 1977-08-15 1979-10-23 Abbott Laboratories Prefilled two-compartment syringe
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
EP0215942B1 (en) 1985-03-15 1995-07-12 Antivirals Inc. Polynucleotide assay reagent and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5001000A (en) 1988-09-26 1991-03-19 E. I. Du Pont De Nemours And Company Process for forming a composite structure of thermoplastic polymer and sheet molding compound
US5114703A (en) 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
JPH03190823A (ja) * 1989-12-21 1991-08-20 Snow Brand Milk Prod Co Ltd エリスロポエチン皮下又は筋肉投与剤
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE69419721T2 (de) 1993-01-12 2000-04-27 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
US5334162A (en) 1993-03-15 1994-08-02 Eli Lilly And Company Cartridge assembly for a lyophilized compound forming a disposable portion of an injector pen and method for same
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5527675A (en) 1993-08-20 1996-06-18 Millipore Corporation Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
DE4331012A1 (de) 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
JP3524974B2 (ja) 1994-12-26 2004-05-10 ブラッコ インターナショナル ビーヴィ プレフィルドシリンジおよびその包装体
US5569193A (en) 1995-03-22 1996-10-29 Abbott Laboratories Syringe system accommodating separately storable prefilled containers for two constituents
US5779668A (en) 1995-03-29 1998-07-14 Abbott Laboratories Syringe barrel for lyophilization, reconstitution and administration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DE19617369A1 (de) 1996-04-30 1997-11-06 Immuno Ag Lagerstabile Fibrinogen-Präparate
US6184037B1 (en) 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US5819998A (en) 1996-09-30 1998-10-13 Everything Kids Knapsack with simulated basketball court
IN184589B (es) 1996-10-16 2000-09-09 Alza Corp
US5819988A (en) 1997-04-01 1998-10-13 Sawhney; Ravi K. Double-barreled syringe with detachable locking mixing tip
US6065645A (en) 1997-04-01 2000-05-23 Discus Dental Impressions, Inc. Double-barreled syringe with detachable locking mixing tip
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US5786571A (en) 1997-05-09 1998-07-28 Lexmark International, Inc. Wrapped temperature sensing assembly
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CN1275916A (zh) 1997-10-15 2000-12-06 旭化成工业株式会社 用于在贮藏/运输中保持血栓调节素含水注射剂质量的方法
WO1999021010A1 (fr) 1997-10-22 1999-04-29 Chugai Seiyaku Kabushiki Kaisha PROCEDE DE SELECTION DE SUBSTANCES INHIBITRICES DE TGF-$g(b)
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
FR2794649B1 (fr) 1999-06-11 2003-04-11 Solutions Biomateriau a base d'un derive de dextrane insolubilise et d'un facteur de croissance, son procede de preparation et ses applications
AUPQ132599A0 (en) 1999-07-01 1999-07-22 Commonwealth Scientific And Industrial Research Organisation Nasogastric enteral formulations
US7030097B1 (en) 1999-07-14 2006-04-18 Cornell Research Foundation, Inc. Controlled nucleic acid delivery systems
EP1072323B1 (de) 1999-07-29 2003-09-10 Wilhelm A. Keller Kartuschen-Austraggerät mit Antrieb für dynamischen Mischer
PT1491208E (pt) 1999-10-04 2010-05-12 Novartis Vaccines & Diagnostic Composições farmacêuticas contendo polipéptido líquidas estabilizadas
US6394314B1 (en) 1999-10-12 2002-05-28 Discus Dental Impressions, Inc. Double-barreled syringe with detachable locking mixing tip
US6443612B1 (en) 1999-12-02 2002-09-03 Wilhelm A. Keller Dynamic mixer
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
CA2430499C (en) 2000-11-30 2012-05-22 Biovalve Technologies, Inc. Injection systems
HU230458B1 (hu) 2000-12-01 2016-07-28 Europäisches Laboratorium für Molekularbiologie (EMBL) Az RNS interferenciát közvetítő kis RNS molekulák
JP2005501814A (ja) 2001-05-16 2005-01-20 バイオマリン ファーマシューティカル インコーポレイテッド ビブリオリシンまたはその改変体を用いるプリオンの破壊
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
BR0211579A (pt) 2001-08-02 2004-07-13 3M Innovative Properties Co Vidro-cerâmica, contas, pluralidade de partìculas abrasivas, artigo abrasivo, e, métodos para abradar uma superfìcie, para fabricar vidro-cerâmica, para fabricar um artigo de vidro-cerâmica e para fabricar partìculas abrasivas
JP4167820B2 (ja) * 2001-10-19 2008-10-22 アルインコ株式会社 デッキプレート走行台車
GB0212405D0 (en) 2002-05-29 2002-07-10 Insignion Holdings Ltd Composition and its therapeutic use
KR20050038008A (ko) * 2002-07-31 2005-04-25 알자 코포레이션 주사용 저장형 조성물 및 이의 용도
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
JP4464395B2 (ja) 2003-03-05 2010-05-19 ヘイローザイム インコーポレイテッド 可溶性ヒアルロニダーゼ糖タンパク質（ｓＨＡＳＥＧＰ）、その調製プロセス、使用およびそれを含む薬学的組成物
WO2004089335A2 (en) 2003-03-31 2004-10-21 Alza Corporation Non-aqueous single phase vehicles and formulations utilizing such vehicles
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
WO2005030119A2 (en) 2003-04-11 2005-04-07 Allergan, Inc. Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
WO2004092361A1 (en) 2003-04-15 2004-10-28 Ista Pharmaceuticals, Inc. Process for isolating and purifing ovine hyaluronidase
US20040247672A1 (en) 2003-05-16 2004-12-09 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions
US20070184084A1 (en) 2003-05-30 2007-08-09 Guohua Chen Implantable elastomeric caprolactone depot compositions and uses thereof
CN102618605B (zh) 2003-06-18 2015-09-02 斯克利普斯研究院 非天然活性氨基酸遗传密码增加
CA2530434A1 (en) 2003-06-23 2005-01-06 Aventis Pasteur, Inc. Immunization method against neisseria meningitidis serogroups a and c
CN1206344C (zh) 2003-07-28 2005-06-15 中国海洋大学 一种用细菌生产岩藻聚糖硫酸酯酶的方法
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
AU2004317954A1 (en) 2003-09-17 2005-10-13 Chiasma, Inc. Compositions capable of facilitating penetration across a biological barrier
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
GB0403938D0 (en) 2004-02-21 2004-03-24 West Pharm Serv Drug Res Ltd Chitosan containing solution
LT2662390T (lt) 2004-06-21 2017-10-10 E. R. Squibb & Sons, L.L.C. Interferono-alfa receptoriaus-1 antikūnai ir jų panaudojimas
DE602004027396D1 (de) 2004-11-25 2010-07-08 Chr Hansen As Verfahren zur Herstellung eines Karminsaürelackes
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060141040A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
CA2595380A1 (en) * 2005-01-28 2006-08-03 Wyeth Stabilized liquid polypeptide formulations
EP1931760A4 (en) 2005-10-07 2010-10-20 Univ Alabama LIQUID, IONIC, MULTIFUNCTIONAL COMPOSITIONS FOR CONVICTING POLYMORPHISM AND PROVIDING BETTER PROPERTIES TO ACTIVE PHARMACEUTICAL, BIOLOGICAL, NUTRITIONAL AND ENERGY INGREDIENTS
CN100416002C (zh) * 2005-10-26 2008-09-03 曲新华 污水再生利用装置
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
CA2634547C (en) 2005-12-20 2016-10-11 Bristol-Myers Squibb Company Stable ctla4 formulation for subcutaneous administration
EP1962907A2 (en) 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
CN1823768A (zh) 2006-01-09 2006-08-30 徐新盛 西咪替丁冻干组合物
US20080071063A1 (en) 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
DE102006005094A1 (de) 2006-02-04 2007-08-09 Degussa Gmbh Titandioxid und Polycarboxylatether enthaltende Dispersion
ITMI20061030A1 (it) 2006-05-26 2007-11-27 Altergon Sa Nuova composizione comprendente glicosamminoglicani a viscosita' controllata e uso di tale composizione nella terapuia della cistite cronica
CU23526B6 (es) 2006-10-03 2010-05-19 Ct Ingenieria Genetica Biotech Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética
WO2008092084A2 (en) 2007-01-26 2008-07-31 Centocor, Inc. Injectable non-aqueous suspension with high concentration of therapeutic agent
ES2660906T3 (es) 2007-05-31 2018-03-26 Anterios, Inc. Nanopartículas de ácido nucleico y usos de las mismas
CN101689450B (zh) 2007-07-20 2012-07-18 应用材料公司 等离子体工艺设备中用于至射频驱动电极的气体传递的射频扼流器
WO2009015367A2 (en) 2007-07-25 2009-01-29 Arizona Board Of Regents For And On Behalf Of Arizona State University Stabilizing proteins using ionic liquids
MX2010001723A (es) 2007-08-17 2010-04-30 Amgen Inc Formulaciones de anticuerpos y moleculas de fusion-fc usando policationes.
CA2701032C (en) 2007-09-27 2021-01-26 Amgen Inc. Pharmaceutical formulations
EA201370191A1 (ru) 2007-10-16 2014-05-30 Фармасайкликс, Инк. КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
NZ602498A (en) * 2007-11-30 2014-08-29 Abbvie Inc Protein formulations and methods of making same
EP2234636A4 (en) 2007-12-21 2013-05-15 Lyotropic Therapeutics Inc FORMULATIONS OF STABILIZED PEPTIDES AND PROTEINS
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US20120251615A1 (en) * 2008-01-18 2012-10-04 Horst Kief Agent for intra-articular injection
WO2009120684A1 (en) * 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
WO2009137471A2 (en) * 2008-05-05 2009-11-12 University Of Miami Azo dye related small molecule modulators of protein-protein interactions
EP2123307A1 (en) * 2008-05-20 2009-11-25 Hexal Ag Method for reducing leachables and extractables in syringes
CA2743789C (en) 2008-11-16 2017-10-31 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
TWI342781B (en) * 2008-12-01 2011-06-01 Univ China Medical Blood sugar-modulating polypeptides
EP2403874A1 (en) 2009-03-06 2012-01-11 Genentech, Inc. Antibody formulation
NZ595694A (en) * 2009-05-04 2013-09-27 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
WO2010132047A1 (en) * 2009-05-14 2010-11-18 Rensselaer Polytechnic Institute Guanosine/gmp gels and uses thereof
EP3018481B1 (en) 2009-05-20 2018-02-21 Sekisui Medical Co., Ltd. Blood coagulation time prolonging agent
ES2569514T3 (es) 2009-06-17 2016-05-11 Biomarin Pharmaceutical Inc. Formulaciones para enzimas lisosómicas
WO2011017070A1 (en) * 2009-07-28 2011-02-10 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
JP2013501058A (ja) * 2009-08-04 2013-01-10 ジェネンテック， インコーポレイテッド 低減された粘性を有する濃縮ポリペプチド製剤
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
JP5734985B2 (ja) 2009-09-17 2015-06-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ ヒアルロニダーゼおよび免疫グロブリンの安定な共製剤およびそれらの使用方法
EP2491123B1 (en) 2009-10-20 2018-04-18 The Regents of The University of California Single molecule nucleic acid nanoparticles
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
PT3721904T (pt) 2009-11-20 2021-11-15 Biocon Ltd Formulações de anticorpo t1h
WO2011069037A2 (en) 2009-12-03 2011-06-09 The University Of North Carolina At Charlotte Stabilization and storage of biological pharmaceutical compositions
WO2011072246A2 (en) 2009-12-10 2011-06-16 Regents Of The University Of Minnesota Tal effector-mediated dna modification
US8715651B2 (en) 2010-01-08 2014-05-06 Chanel Parfums Beaute Use of at least one extract of flowers of Camellia japonica alba plena for moisturizing the skin
WO2011095543A1 (en) 2010-02-04 2011-08-11 Csl Behring Ag Immunoglobulin preparation
EP3708190A1 (en) 2010-02-26 2020-09-16 Novo Nordisk A/S Stable antibody containing compositions
NZ602685A (en) * 2010-03-01 2014-10-31 Cytodyn Inc Concentrated protein formulations and uses thereof
WO2011109415A2 (en) 2010-03-02 2011-09-09 Amgen Inc. Reducing viscosity of pharmaceutical formulations
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US9072668B2 (en) * 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
JP2013522313A (ja) 2010-03-17 2013-06-13 アボツト・リサーチ・ベー・フエー 抗神経成長因子（ｎｇｆ）抗体組成物
EP2552482A2 (en) * 2010-03-31 2013-02-06 Université de Genève Stabilized antibody preparations and uses thereof
CN101851267A (zh) 2010-04-22 2010-10-06 江南大学 一种抗体保护剂及其应用
MX2012012743A (es) 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
BR112012028920B1 (pt) * 2010-05-14 2021-03-23 Amgen Inc. Formulações líquidas estéreis de anticorpo de alta concentração e método para reduzir a viscosidade de uma formulação de proteína
GB201012179D0 (en) 2010-07-20 2010-09-01 Future Injection Technologies Injection device
TWI603739B (zh) * 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
US8936827B2 (en) 2011-02-25 2015-01-20 Abbott Cardiovascular Systems Inc. Methods of loading a hollow stent with a drug or drug formulation
SG193963A1 (en) 2011-04-07 2013-11-29 Glaxosmithkline Llc Formulations with reduced viscosity
AU2012243126A1 (en) 2011-04-07 2013-10-17 Glaxosmithkline Llc Formulations with reduced viscosity
CN103619368B (zh) 2011-05-12 2017-02-08 拜耳医药保健有限公司 具有用于控制注射程序的不同系统的流体注射系统
RU2485133C2 (ru) 2011-05-30 2013-06-20 Закрытое Акционерное Общество "Фарм-Синтез" Белково-полипептидный комплекс, обладающий тканеспецифическим регенеративно-репаративным и омолаживающим действием на кожную ткань, способ его получения и фармацевтическая композиция на его основе
CN102349895B (zh) 2011-09-28 2013-04-10 海南良方医药有限公司 一种注射用西咪替丁组合物及其制备方法
EP2771300B1 (en) 2011-10-25 2017-12-20 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
KR101759694B1 (ko) 2011-10-28 2017-07-19 인테그리티 바이오, 아이엔씨. 아미노산을 함유하는 단백질 제제
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
WO2013096835A1 (en) * 2011-12-23 2013-06-27 Abbvie Inc. Stable protein formulations
WO2013112986A1 (en) 2012-01-27 2013-08-01 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
US10160808B2 (en) 2012-02-16 2018-12-25 Santarus, Inc. Anti-VLA1 (CD49A) antibody pharmaceutical compositions
US9574193B2 (en) 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
US20160002624A1 (en) 2012-05-17 2016-01-07 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
SG10201709555SA (en) 2012-05-18 2017-12-28 Genentech Inc High-concentration monoclonal antibody formulations
US10010513B2 (en) 2012-05-25 2018-07-03 Novartis Ag Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
PT2800811T (pt) 2012-05-25 2017-08-17 Univ California Métodos e composições para modificação de adn alvo dirigida por arn e para modulação dirigida por arn de transcrição
NZ702342A (en) 2012-06-21 2016-07-29 Ucb Pharma Sa Pharmaceutical formulation
EP3494997B1 (en) 2012-07-25 2019-09-18 The Broad Institute, Inc. Inducible dna binding proteins and genome perturbation tools and applications thereof
CN104704001B (zh) 2012-08-09 2019-02-12 罗切格利卡特公司 Asgpr抗体及其用途
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
FR2995214B1 (fr) 2012-09-10 2014-11-21 Adocia Solution a viscosite reduite de proteine a concentration elevee
EP2968873A4 (en) 2013-03-13 2016-10-26 Applied Cardiovascular Solutions Llc METHODS, COMPOSITIONS AND DEVICES FOR OCCLUSION OF CAVITIES AND PASSAGES
US9669242B2 (en) 2013-07-01 2017-06-06 L'oreal Compositions containing at least two phenolic compounds, a lipid-soluble antioxidant and at least one hydrotrope for cosmetic use
EP3043775B1 (en) 2013-09-11 2020-11-04 Eagle Biologics, Inc. Liquid protein formulations containing viscosity-lowering agents
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
KR102497368B1 (ko) * 2014-10-01 2023-02-10 이글 바이올로직스 인코포레이티드 점도-저하제를 함유하는 폴리삭카라이드 및 핵산 제형
US10812184B1 (en) 2019-04-03 2020-10-20 Board Of Trustees Of The University Of Alabama, For And On Behalf Of The University Of Alabama In Huntsville Signal analysis systems and methods

Also Published As

Publication number Publication date
HK1226309A1 (zh) 2017-09-29
AU2020202407A1 (en) 2020-05-07
US10849977B2 (en) 2020-12-01
AU2014318637B2 (en) 2020-01-23
HK1225979A1 (zh) 2017-09-22
KR102295633B1 (ko) 2021-08-30
JP6469113B2 (ja) 2019-02-13
BR112016005309A2 (pt) 2017-08-01
HK1225982A1 (zh) 2017-09-22
CN105705139B (zh) 2019-07-26
WO2015038811A2 (en) 2015-03-19
BR112016005309A8 (pt) 2021-06-22
ES2841134T3 (es) 2021-07-07
JP2016530321A (ja) 2016-09-29
KR102651018B1 (ko) 2024-03-27
CA2923843A1 (en) 2015-03-19
NZ717918A (en) 2021-05-28
JP2019073563A (ja) 2019-05-16
SG10201806539XA (en) 2018-08-30
KR20220123552A (ko) 2022-09-07
CN110559435B (zh) 2023-10-20
CN105722500A (zh) 2016-06-29
AU2014318725A1 (en) 2016-04-07
CN110496099B (zh) 2022-06-21
US10179172B2 (en) 2019-01-15
US20180153997A1 (en) 2018-06-07
WO2015038818A2 (en) 2015-03-19
JP2019178176A (ja) 2019-10-17
MX2021012048A (es) 2021-11-03
CA2923843C (en) 2022-07-12
JP2020203956A (ja) 2020-12-24
US20180177875A1 (en) 2018-06-28
JP6564512B2 (ja) 2019-08-21
ES2837629T3 (es) 2021-07-01
AU2014318691A1 (en) 2016-04-07
AU2014318725B2 (en) 2020-01-23
CA2923859A1 (en) 2015-03-19
AU2020202408A1 (en) 2020-05-07
EP3043776B1 (en) 2024-01-03
KR20160055243A (ko) 2016-05-17
US11986526B2 (en) 2024-05-21
RU2710542C2 (ru) 2019-12-27
CA2923844A1 (en) 2015-03-19
SI3043772T1 (sl) 2023-10-30
EP3043772B1 (en) 2023-07-19
EP3791862A1 (en) 2021-03-17
RU2016113385A (ru) 2017-10-16
CA2924069A1 (en) 2015-03-19
EP4272763A2 (en) 2023-11-08
AU2023229619A1 (en) 2023-10-05
EP3043774B1 (en) 2020-11-04
US20150071922A1 (en) 2015-03-12
AU2020202240B2 (en) 2023-02-09
AU2023251546A1 (en) 2023-11-16
ZA201601968B (en) 2018-07-25
JP7214697B2 (ja) 2023-01-30
EP3043772A1 (en) 2016-07-20
AU2020202407B2 (en) 2023-07-13
EP3791862B1 (en) 2024-05-29
SG10201913952TA (en) 2020-03-30
SI3043774T1 (sl) 2021-01-29
JP6412575B2 (ja) 2018-10-24
CN105722501A (zh) 2016-06-29
JP6515105B2 (ja) 2019-05-15
JP6774484B2 (ja) 2020-10-21
JP2019142985A (ja) 2019-08-29
JP2023021352A (ja) 2023-02-10
AU2023200941A1 (en) 2023-03-30
MX2021012049A (es) 2021-11-03
RU2019140607A3 (es) 2022-04-18
SG11201601728YA (en) 2016-04-28
JP6463581B2 (ja) 2019-02-06
JP2018199735A (ja) 2018-12-20
CN105848636A (zh) 2016-08-10
AU2014318696B2 (en) 2020-01-23
US20150071925A1 (en) 2015-03-12
MX2016003183A (es) 2016-11-14
KR20210110396A (ko) 2021-09-07
MX2016003182A (es) 2017-03-31
ES2959451T3 (es) 2024-02-26
CN105705139A (zh) 2016-06-22
SG10201809401XA (en) 2018-11-29
US9913905B2 (en) 2018-03-13
CA2924069C (en) 2021-11-02
US9833513B2 (en) 2017-12-05
IL244430B (en) 2020-06-30
ZA201802108B (en) 2022-04-28
CN105848636B (zh) 2020-02-21
NZ756401A (en) 2021-05-28
CA2923859C (en) 2021-11-23
JP2016530318A (ja) 2016-09-29
CN111202711B (zh) 2022-06-21
EP3043774A2 (en) 2016-07-20
EP3043775B1 (en) 2020-11-04
SG10201913950XA (en) 2020-03-30
ZA201801669B (en) 2021-07-28
WO2015038818A3 (en) 2015-07-16
RU2016113283A (ru) 2017-10-17
KR102435648B1 (ko) 2022-08-25
WO2015038777A1 (en) 2015-03-19
AU2014318637A1 (en) 2016-04-07
US9925263B2 (en) 2018-03-27
CN111202711A (zh) 2020-05-29
US20150071921A1 (en) 2015-03-12
WO2015038782A1 (en) 2015-03-19
RU2016113283A3 (es) 2018-07-27
JP6840797B2 (ja) 2021-03-10
AU2014318725A2 (en) 2019-02-14
IL275388B1 (en) 2024-06-01
AU2014318691B2 (en) 2020-01-23
NZ717944A (en) 2021-06-25
CN105722501B (zh) 2019-07-26
CN105722500B (zh) 2019-08-30
JP6768858B2 (ja) 2020-10-14
EP3043776A1 (en) 2016-07-20
JP2019056006A (ja) 2019-04-11
IL244433B (en) 2020-07-30
US10821183B2 (en) 2020-11-03
IL244433A0 (en) 2016-04-21
AU2020202408B2 (en) 2023-09-21
CN110559435A (zh) 2019-12-13
HK1225980A1 (zh) 2017-09-22
SI3043776T1 (sl) 2024-03-29
EP3043775A2 (en) 2016-07-20
IL275388A (en) 2020-07-30
IL244430A0 (en) 2016-04-21
US10646571B2 (en) 2020-05-12
US20210030877A1 (en) 2021-02-04
NZ756260A (en) 2021-06-25
SI3043775T1 (sl) 2021-01-29
AU2020202240A1 (en) 2020-04-23
AU2014318696A1 (en) 2016-04-07
KR20240042200A (ko) 2024-04-01
US20150071920A1 (en) 2015-03-12
EP4272763A3 (en) 2024-02-14
KR102289825B1 (ko) 2021-08-17
CA2923844C (en) 2022-07-26
JP6941137B2 (ja) 2021-09-29
SG11201601730TA (en) 2016-04-28
US20180177876A1 (en) 2018-06-28
RU2019140607A (ru) 2020-05-29
HK1225981A1 (zh) 2017-09-22
MX2021005907A (es) 2021-06-23
RU2675824C2 (ru) 2018-12-25
US20210085792A1 (en) 2021-03-25
CN110496099A (zh) 2019-11-26
ES2972527T3 (es) 2024-06-13
ZA202102906B (en) 2023-12-20
US10821184B2 (en) 2020-11-03
WO2015038811A3 (en) 2015-07-23
EP3808338A1 (en) 2021-04-21
US11819550B2 (en) 2023-11-21
US20240181063A1 (en) 2024-06-06
US20210038718A1 (en) 2021-02-11
JP2016534141A (ja) 2016-11-04
KR20160054009A (ko) 2016-05-13
US20180085463A1 (en) 2018-03-29
JP2016530319A (ja) 2016-09-29

Similar Documents

Publication Publication Date Title
ZA202102906B (en) Liquid protein formulations containing viscosity-lowering agents
SG10201902915VA (en) Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
MX2020009411A (es) Capsula resistente al abuso.
MX361061B (es) Composicion farmaceutica liquida.
WO2016172396A3 (en) Multi-chamber sequential delivery syringe
HK1256027A1 (zh) 用於以輸注或注射形式進行靜脈給藥的左西孟旦以及輸注濃縮液的改善配方
NZ728401A (en) High purity oritavancin and method of producing same
WO2015034870A3 (en) Double-chamber mixing syringe and method of use
WO2016100949A3 (en) Method and compositions for dissolving or solubilizing therapeutic agents
TN2017000011A1 (en) Aqueous formulation comprising paracetamol and ibuprofen.
EP3777924A4 (en) PRE-FILLED SYRINGE, LIQUID MEDICATION DELIVERY SYSTEM AND SYRINGE PUMP
MX2017008000A (es) Sistema de inyeccion de un solo uso.
MY191043A (en) Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereof
PH12017501005A1 (en) Injectable formulations of paracetamol
EA201391512A1 (ru) Твердая фармацевтическая композиция
EA027609B8 (ru) Способ получения интерферона бета-1альфа и фармацевтическая композиция, содержащая интерферон бета-1альфа
EA201600331A1 (ru) Фармацевтическая композиция в форме раствора для внутривенного и внутримышечного введения и способ ее получения